Cargando…

A Simple Method for the Prediction of Human Concentration–Time Profiles and Pharmacokinetics of Antibody–Drug Conjugates (ADC) from Rats or Monkeys

Knowledge of human concentration–time profiles from animal data can be useful during early drug development. The objective of this study is to predict human concentration–time profiles of antibody–drug conjugates (ADCs) and subsequently predict pharmacokinetic parameters in humans from rats or monke...

Descripción completa

Detalles Bibliográficos
Autor principal:	Mahmood, Iftekhar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219807/ https://www.ncbi.nlm.nih.gov/pubmed/35735361 http://dx.doi.org/10.3390/antib11020042

Ejemplares similares

Effect of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Antibody–Drug Conjugates (ADCs)
por: Mahmood, Iftekhar
Publicado: (2021)

Interspecies Scaling of Antibody–Drug Conjugates (ADC) for the Prediction of Human Clearance
por: Mahmood, Iftekhar
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Methods to Design and Synthesize Antibody-Drug Conjugates (ADCs)
por: Yao, Houzong, et al.
Publicado: (2016)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Potential of antibody–drug conjugates (ADCs) for cancer therapy
por: Marei, Hany E., et al.
Publicado: (2022)

Enzyme-linked immunosorbent assays for quantification of MMAE-conjugated ADCs and total antibodies in cynomolgus monkey sera
por: Pei, Min, et al.
Publicado: (2022)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
por: Janthur, Wolf-Dieter, et al.
Publicado: (2012)

Antibody structure and engineering considerations for the design and function of Antibody Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2017)

Semi-mechanistic Multiple-Analyte Pharmacokinetic Model for an Antibody-Drug-Conjugate in Cynomolgus Monkeys
por: Lu, Dan, et al.
Publicado: (2014)

New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development
por: Koster, Kira-Lee, et al.
Publicado: (2022)

From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)
por: Mantaj, Julia, et al.
Publicado: (2016)

Effectiveness of Antibody-Drug Conjugate (ADC): Results of In Vitro and In Vivo Studies
por: Kang, Xiuhua, et al.
Publicado: (2018)

Site-Specific Antibody Conjugation for ADC and Beyond
por: Zhou, Qun
Publicado: (2017)

Prediction of non-linear pharmacokinetics in humans of an antibody-drug conjugate (ADC) when evaluation of higher doses in animals is limited by tolerability: Case study with an anti-CD33 ADC
por: Figueroa, Isabel, et al.
Publicado: (2018)

Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation
por: Cini, Elena, et al.
Publicado: (2018)

Antibody–Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review
por: Lambert, John M., et al.
Publicado: (2017)

Antibody–Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors
por: McNamara, Blair, et al.
Publicado: (2023)

Optimization of Tubulysin Antibody–Drug Conjugates: A Case Study in Addressing ADC Metabolism
por: Tumey, L. Nathan, et al.
Publicado: (2016)

Characterization and in vitro data of antibody drug conjugates (ADCs) derived from heterotrifunctional linker designed for the site-specific preparation of dual ADCs
por: Kumar, Amit, et al.
Publicado: (2018)

Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)—A Necessity for Future ADC Research and Development
por: Hammood, Manar, et al.
Publicado: (2021)

TOOLBOX: Strep-Tagged nano-assemblies of antibody-drug-conjugates (ADC) for modular and conditional cancer drugging
por: Tremante, Elisa, et al.
Publicado: (2021)

A GFR-Based Method to Predict the Effect of Renal Impairment on the Exposure or Clearance of Renally Excreted Drugs: A Comparative Study Between a Simple GFR Method and a Physiologically Based Pharmacokinetic Model
por: Mahmood, Iftekhar
Publicado: (2020)

A Single Animal Species-Based Prediction of Human Clearance and First-in-Human Dose of Monoclonal Antibodies: Beyond Monkey
por: Mahmood, Iftekhar
Publicado: (2021)

A Simple Method for the Prediction of Therapeutic Proteins (Monoclonal and Polyclonal Antibodies and Non-Antibody Proteins) for First-in-Pediatric Dose Selection: Application of Salisbury Rule
por: Mahmood, Iftekhar
Publicado: (2022)

Antibody-Drug Conjugates (ADC) Against Cancer Stem-Like Cells (CSC)—Is There Still Room for Optimism?
por: Marcucci, Fabrizio, et al.
Publicado: (2019)

Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers
por: Esapa, Benjamina, et al.
Publicado: (2023)

Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions
por: Ferraro, Emanuela, et al.
Publicado: (2021)

Society of Gynecologic Oncology Journal Club: Controversial conversations in Gynecologic cancer – The ABCs of ADCs (Antibody drug Conjugates)()
por: Martin, J., et al.
Publicado: (2023)

Preclinical Pharmacokinetic Considerations for the Development of Antibody Drug Conjugates
por: Kamath, Amrita V., et al.
Publicado: (2014)

Small-Format Drug Conjugates: A Viable Alternative to ADCs for Solid Tumours?
por: Deonarain, Mahendra P., et al.
Publicado: (2018)

Does sacituzumab-govitecan act as a conventional antibody drug conjugate (ADC), a prodrug of SN-38 or both?
por: Santi, Daniel V., et al.
Publicado: (2021)

Preclinical Efficacy of the Antibody–Drug Conjugate CLDN6–23-ADC for the Treatment of CLDN6-Positive Solid Tumors
por: McDermott, Martina S.J., et al.
Publicado: (2023)

Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody‐Drug Conjugates
por: Li, Chunze, et al.
Publicado: (2020)

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2015)

A RAGE-Targeted Antibody-Drug Conjugate: Surface Plasmon Resonance as a Platform for Accelerating Effective ADC Design and Development
por: Healey, Gareth D., et al.
Publicado: (2019)

Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel
por: Bianchini, Giampaolo, et al.
Publicado: (2022)

Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (Trop-2) and precision treatment of breast cancer
por: Stenvang, Jan, et al.
Publicado: (2022)

Application of a Plug-and-Play Immunogenicity Assay in Cynomolgus Monkey Serum for ADCs at Early Stages of Drug Development
por: Carrasco-Triguero, Montserrat, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lcmgu7df4lkddk3vsbkfasforq